Skip to main content

Health condition · Clinically reviewed

Vitiligo, autoimmune pigment loss — with new JAK-based treatments.

Immune-mediated destruction of melanocytes causing patches of pigment loss. Modern treatments include topical calcineurin inhibitors, phototherapy, and new topical JAK inhibitors (ruxolitinib).

A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE CKS, BAD and the Vitiligo Society you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK guidance including topical JAK inhibitors (ruxolitinib cream) for non-segmental vitiligo.

Key facts

Vitiligo at a glance.

The essentials, in plain English — what it is, how common it is, how it’s diagnosed, and how it’s treated in the UK today.

  • What it is

    An autoimmune condition in which the immune system destroys melanocytes — the pigment-producing cells of the skin.

  • How common

    Affects roughly 1% of the UK population, across every age, sex and skin tone.

  • Two main types

    Segmental (one area, often stable) and non-segmental (generalised, symmetrical and more common).

  • Autoimmune company

    Often coexists with other autoimmune conditions — most commonly thyroid disease and coeliac disease.

  • A landmark new therapy

    Ruxolitinib cream — a topical JAK inhibitor — is the first drug licensed specifically to repigment non-segmental vitiligo.

  • Psychological impact

    The visible, unpredictable nature of vitiligo is often underestimated — mood and anxiety deserve equal attention.

Why this guide matters

A quiet revolution in vitiligo care.

Vitiligo used to sit in a therapeutic corner. It doesn’t anymore. The three points below shape everything else on this page.

  • It’s autoimmune, not cosmetic

    Vitiligo belongs to the same family as thyroid disease and coeliac — worth screening for and worth taking seriously.

  • Modern treatments genuinely work

    Topical JAK inhibitors and narrowband UVB have changed what’s achievable, especially on the face.

  • The psychological impact is real

    A visible, unpredictable condition deserves mental-health support alongside skin treatment.

How the diagnosis is made

From first white patch to a clear plan.

The steps a UK GP or dermatologist will normally follow, in order — so you know what to expect and why.

  1. 01

    Recognising

    Clinical exam with Wood’s lamp

    A handheld UV lamp accentuates depigmented patches and confirms true loss of melanin rather than a lighter shade.

  2. 02

    Recognising

    Ruling out mimics

    Pityriasis alba, tinea versicolor, post-inflammatory hypopigmentation and halo naevi can look similar and should be excluded.

  3. 03

    Confirming

    Autoimmune bloods

    Thyroid function is checked routinely; coeliac serology and other autoantibodies are added if the history suggests it.

  4. 04

    Confirming

    Photographic mapping

    Standardised photographs record baseline extent so response — or progression — can be judged objectively later.

  5. 05

    Confirming

    DLQI life-impact score

    A short questionnaire captures how much vitiligo affects daily life — a legitimate driver of treatment intensity.

  6. 06

    Managing

    Dermatology referral

    For confirmation, treatment planning, phototherapy access and — where indicated — topical JAK inhibitor prescribing.

  7. 07

    Managing

    Honest expectations

    Repigmentation is slow, uneven and site-dependent — the face responds best, hands and lips least. Honesty upfront prevents disappointment.

Typical timeline: a first visit to a settled plan in weeks, not months.

Symptoms

What vitiligo actually looks like.

The classic pattern of symmetrical white patches — and the features that mean it’s time to escalate.

  • White symmetrical patches

    Sharply demarcated, milky-white patches — the hallmark of non-segmental vitiligo.

  • Symmetrical distribution

    Mirror-image patches on both sides of the body suggest the generalised (non-segmental) form.

  • Segmental type

    A single band or patch confined to one side, often stable after an initial phase of spread.

  • Lips (mucosal)

    Depigmentation of the vermilion border and inside the mouth — a common and cosmetically sensitive site.

  • Hands (acral)

    Fingertips and the backs of the hands — a classic site, and among the hardest to repigment.

  • Hair depigmentation

    Leukotrichia — white hairs within a patch — is a marker of loss of follicular melanocytes and predicts poorer response.

  • Sun-exposed onset

    Patches often first appear on the face, neck and hands — sites of chronic UV exposure and everyday scrutiny.

  • Red flag: rapid spread

    Rapidly expanding vitiligo warrants urgent dermatology referral to consider systemic treatment and slow progression.

Treatment

How vitiligo is treated in the UK.

Topicals and phototherapy first, with a modern ladder that now includes topical JAK inhibitors and specialist surgical options.

  • Topical corticosteroid

    A moderate-to-potent steroid is often the first-line treatment on the body — used in short pulses to avoid skin thinning.

  • Topical calcineurin inhibitor

    Tacrolimus and pimecrolimus are steroid-sparing options — particularly useful on the face, eyelids and skin folds.

  • Ruxolitinib cream (JAK inhibitor)

    The first drug licensed to repigment non-segmental vitiligo — a topical JAK inhibitor with strong evidence for facial response.

  • Narrowband UVB phototherapy

    The workhorse of vitiligo care — 2–3 sessions a week in dermatology units, often over many months.

  • Excimer laser

    Targeted UVB for small, localised patches — useful when whole-body phototherapy isn’t warranted.

  • Melanocyte transplant

    Specialist surgical grafting of pigment cells for stable, segmental vitiligo unresponsive to medical treatment.

  • Camouflage make-up

    Medical-grade cover creams (Skin Camouflage Service, Changing Faces) can be life-changing while other treatments work.

  • Sun protection

    Depigmented skin has no natural UV defence — daily SPF and sensible cover reduce burn risk and photodamage.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or dermatologist knows your skin and history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE CKS. Vitiligo — diagnosis and management.

  • British Association of Dermatologists (BAD). Patient information leaflet on vitiligo.

  • The Vitiligo Society UK. Patient information, camouflage and support.

  • World Vitiligo Day (25 June). International awareness and advocacy resources.

Red flags

When vitiligo needs urgent attention.

Most of the time, vitiligo is a stable long-term condition. These are the situations where it isn’t — and you should act.

  • Rapidly spreading vitiligo

    New patches appearing over weeks rather than months — dermatology referral to consider systemic treatment to slow progression.

  • Segmental + non-segmental mixed pattern

    An unusual overlap that changes prognosis and treatment — deserves specialist assessment.

  • New autoimmune features

    Symptoms of thyroid disease, coeliac disease or type 1 diabetes should trigger relevant blood tests.

  • Psychological distress

    Low mood, social withdrawal or shame linked to appearance — treat as a genuine clinical priority, not a cosmetic aside.

  • Post-treatment koebnerisation

    New patches appearing at sites of skin trauma or friction — worth flagging to your dermatologist.

  • Vitiligo + hearing loss

    Consider Alezzandrini syndrome — a rare association of unilateral vitiligo, hearing loss and retinal changes.

  • Post-transplant recurrence

    Loss of pigment in previously grafted areas — needs specialist review to guide the next step.

  • Uveitis with vitiligo

    Eye pain, redness or blurred vision — consider Vogt–Koyanagi–Harada syndrome and refer urgently to ophthalmology.

  • Depression or suicidality

    The cosmetic impact of vitiligo can be severe — take any expression of hopelessness seriously and seek same-day help.

Living with it

A long-term condition, but a very manageable one.

Four things that make the biggest difference day to day — sun protection, camouflage, community and asking for the newest options.

A quiet reminder

Consistency beats intensity, every time.

Repigmentation takes months. Small, steady treatment kept up patiently does more than a heroic burst that doesn’t last.

  1. 01 Sun

    SPF is medicine, not vanity

    Depigmented skin has no melanin to buffer UV — daily broad-spectrum SPF protects skin and keeps contrast down.

  2. 02 Camouflage

    Cover-up, not a cover-story

    Medical camouflage — free through the NHS-referred Changing Faces service — is a legitimate tool, not a compromise.

  3. 03 Community

    You’re not alone

    The Vitiligo Society UK and peer groups genuinely help — hearing others’ stories reframes the condition.

  4. 04 Escalate

    Ask about the new options

    If your treatment hasn’t been reviewed since 2023, ask about topical JAK inhibitors and modern phototherapy protocols.

Frequently asked

Everything we get asked about vitiligo.

Quick answers on treatments, JAK inhibitors, phototherapy and when to worry.

  • What is vitiligo?

    An autoimmune condition where the immune system destroys melanocytes — the skin’s pigment cells — leaving sharply-defined white patches. It affects around 1% of people and any age or skin tone.

  • Is vitiligo contagious or dangerous?

    No. Vitiligo is not infectious and is not itself dangerous, but depigmented skin burns easily and is linked to other autoimmune conditions worth screening for.

  • Can vitiligo be cured?

    There is no cure yet, but treatments can slow spread and restore pigment in many people — especially with early treatment and modern options like ruxolitinib cream and narrowband UVB.

  • What is ruxolitinib cream?

    A topical JAK inhibitor and the first drug licensed specifically to repigment non-segmental vitiligo. Evidence is strongest for the face; it is prescribed under specialist care.

  • Does the NHS treat vitiligo?

    Yes — first-line topicals and referral for phototherapy are available on the NHS. Camouflage services through Changing Faces are also NHS-referred and free at the point of use.

  • When should I see a doctor urgently?

    Rapidly spreading vitiligo, new eye symptoms, hearing changes, or significant low mood — book a same-day GP appointment and ask about dermatology referral.

WhatsApp Call us
Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

Confidential. We respond within one working day.